

PTO/SB/08A (08-03)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/502,001
				Filing Date	July 19, 2004
				First Named Inventor	Malek, Nisar P.
				Art Unit	1632
				Examiner Name	Unassigned
Sheet	1	of	4	Attorney Docket Number	14538A-006610US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
VB	AA	US-5,958,769	09-28-1999	Roberts <i>et al.</i>	
VB	AB	US-6,242,575	06-05-2001	Massague <i>et al.</i>	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature	/Valarie Bertoglio/	Date Considered	05/31/2006
-----------------------	---------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60542380 v1




PTO/SB/08B (08-03)

Substitute for form 14-001 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/502,001		
		Filing Date	July 19, 2004		
		First Named Inventor	Malek, Nisar P.		
		Art Unit	1632		
		Examiner Name	Unassigned		
Sheet	2	of	4	Attorney Docket Number	14538A-006610US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
VB	AC	AGRAWAL, D. <i>et al.</i> , "Repression of p27 <sup>Kip1</sup> synthesis by platelet-derived growth factor in BALB/c 3T3 cells," <i>Mol. Cell. Biol.</i> , 16(8):4327-4336 (Aug. 1996).		
VB	AD	BAI, C. <i>et al.</i> , "SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box," <i>Cell</i> , 86(2):263-274 (Jul. 26, 1996).		
VB	AE	CARRANO, A. <i>et al.</i> , "SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27," <i>Nat. Cell. Biol.</i> , 1(4):193-199 (Aug. 1999).		
VB	AF	FELDMAN, R.M. <i>et al.</i> , "A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p," <i>Cell</i> , 91(2):221-230 (Oct. 17, 1997).		
VB	AG	FERO, M. <i>et al.</i> , "A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 <sup>Kip1</sup> -deficient mice," <i>Cell</i> , 85(5):733-744 (May 31, 1996).		
VB	AH	FRIEDRICH, G. and SORIANO, P., "Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice," <i>Genes Dev.</i> , 5(9):1513-1523 (Sept. 1991).		
VB	AI	GOULD, K. <i>et al.</i> , "Phosphorylation at Thr167 is required for <i>Schizosaccharomyces pombe</i> p34 <sup>cdc2</sup> function," <i>EMBO J.</i> , 10(11):3297-3309 (Nov. 1991).		
VB	AJ	HANNON, G. and BEACH, D., "p15 <sup>INK4B</sup> is a potential effector of TGF- $\beta$ -induced cell cycle arrest," <i>Nature</i> , 371(6494):257-261 (Sept. 15, 1994).		
VB	AK	HATAKEYAMA, M. <i>et al.</i> , "The cancer cell and the cell cycle clock," <i>Cold Spring Harb. Symp. Quant. Biol.</i> , 59:1-10 (1994).		
VB	AL	HENGST, L. and REED, S., "Translational control of p27 <sup>Kip1</sup> accumulation during the cell cycle," <i>Science</i> , 271(5257):1861-1864 (Mar. 29, 1996).		
VB	AM	HOLMES, J. and SOLOMON, M., "A predictive scale for evaluating cyclin-dependent kinase substrates. A comparison of p34 <sup>cdc2</sup> and p33 <sup>cdk2</sup> ," <i>J. Biol. Chem.</i> , 271(41):25240-25246 (Oct. 11, 1996).		
VB	AN	JEFFREY, P. <i>et al.</i> , "Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex," <i>Nature</i> , 376(6538):313-320 (Jul. 27, 1995).		
VB	AO	KATO, J. <i>et al.</i> , "Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 <sup>Kip1</sup> ) of cyclin-dependent kinase 4 activation," <i>Cell</i> , 79(3):487-496 (Nov. 4, 1994).		
VB	AP	KOFF, A. <i>et al.</i> , "Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF- $\beta$ ," <i>Science</i> , 260(5107):536-539 (Apr. 23, 1993).		
VB	AQ	LEE, MH <i>et al.</i> , "Cloning of p57 <sup>KIP2</sup> , a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution," <i>Genes Dev.</i> , 9(6):639-649 (Mar. 15, 1995).		
Examiner Signature	/Valarie Bertoglio/		Date Considered	05/31/2006

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/502,001		
		Filing Date	July 19, 2004		
		First Named Inventor	Malek, Nisar P.		
		Art Unit	1632		
		Examiner Name	Unassigned		
Sheet	3	of	4	Attorney Docket Number	14538A-006610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
VB	AR	LEONE, G. <i>et al.</i> , "Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F," <i>Nature</i> , 387(6631):422-426 (May 22, 1997).	
VB	AS	MALEK, N. <i>et al.</i> , "A mouse knock-in model exposes sequential proteolytic pathways that regulate p27 <sup>Kip1</sup> in G1 and S phase," <i>Nature</i> , 413(6853):323-327 (Sept. 20, 2001).	
VB	AT	MILLARD, S.S. <i>et al.</i> , "A U-rich element in the 5' untranslated region is necessary for the translation of p27 mRNA," <i>Mol. Cell. Biol.</i> , 20(16):5947-5959 (Aug. 2000).	
VB	AU	MILLARD, S.S. <i>et al.</i> , "Enhanced ribosomal association of p27 <sup>Kip1</sup> mRNA is a mechanism contributing to accumulation during growth arrest," <i>J. Biol. Chem.</i> , 272(11):7093-7098 (Mar. 14, 1997).	
VB	AV	MONTAGNOLI, A. <i>et al.</i> , "Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation," <i>Genes Dev.</i> , 13(9):1181-1189 (May 1, 1999).	
VB	AW	MORGAN, D., "Principles of CDK regulation," <i>Nature</i> , 374(6518):131-134 (Mar. 9, 1995).	
VB	AX	MORIMOTO, M. <i>et al.</i> , "Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF <sup>Skp2</sup> toward p27 <sup>Kip1</sup> ," <i>Biochem. Biophys. Res. Commun.</i> , 270(3):1093-1096 (Apr. 21, 2000).	
VB	AY	MÜLLER, D. <i>et al.</i> , "Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes," <i>Oncogene</i> , 15(21):2561-2576 (Nov. 20, 1997).	
VB	AZ	NAGY, A. <i>et al.</i> , "Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles," <i>Curr. Biol.</i> , 8(11):661-664 (May 21, 1998).	
VB	BA	NOURSE, J. <i>et al.</i> , "Interleukin-2-mediated elimination of the p27 <sup>Kip1</sup> cyclin-dependent kinase inhibitor prevented by rapamycin," <i>Nature</i> , 372(6506):570-573 (Dec. 8, 1994).	
VB	BB	O'HAGAN, R. <i>et al.</i> , "Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression," <i>Genes Dev.</i> , 14(17):2185-2191 (Sept. 1, 2000).	
VB	BC	PARDEE, A., "A restriction point for control of normal animal cell proliferation," <i>Proc. Natl. Acad. Sci. USA.</i> , 71(4):1286-1290 (Apr. 1974).	
VB	BD	POLYAK, K. <i>et al.</i> , "Cloning of p27 <sup>Kip1</sup> , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals," <i>Cell</i> , 78(1):59-66 (Jul. 15, 1994).	
VB	BE	ROLFE, M. <i>et al.</i> , "The ubiquitin-mediated proteolytic pathway as a therapeutic area," <i>J. Mol. Med.</i> , 75(1):5-17 (Jan. 1997).	
VB	BF	SÉRRANO, M. <i>et al.</i> , "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4," <i>Nature</i> , 366(6456):704-707 (Dec. 16, 1993).	

Examiner Signature	/Valarie Bertoglio/	Date Considered	05/31/2006
--------------------	---------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form 10/198/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/502,001		
		Filing Date	July 19, 2004		
		First Named Inventor	Malek, Nisar P.		
		Art Unit	1632		
		Examiner Name	Unassigned		
Sheet	4	of	4	Attorney Docket Number	14538A-006610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
VB	BG	SHEAFF, R. et al., "Cyclin E-CDK2 is a regulator of p27 <sup>Kip1</sup> ," <i>Genes Dev.</i> , 11(11):1464-1478 (Jun. 1, 1997).	
VB	BH	SHERR, C. and ROBERTS, J. "CDK inhibitors: positive and negative regulators of G <sub>1</sub> -phase progression," <i>Genes Dev.</i> , 13(12):1501-1512 (Jun. 15, 1999).	
VB	BI	SHILO, B.Z. and WEINBERG, R., "DNA sequences homologous to vertebrate oncogenes are conserved in <i>Drosophila melanogaster</i> ," <i>Proc. Natl. Acad. Sci. USA.</i> , 78(11):6789-6792 (Nov. 1981).	
VB	BJ	SKOWYRA, D. et al., "F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex," <i>Cell</i> , 91(2):209-219 (Oct. 17, 1997).	
VB	BK	SOLOMON, M. et al., "CAK, the p34 <sup>cdc2</sup> activating kinase, contains a protein identical or closely related to p40 <sup>MO15</sup> ," <i>EMBO J.</i> , 12(8):3133-3142 (Aug. 1993).	
VB	BL	SOLOMON, M. et al., "Role of phosphorylation in p34 <sup>cdc2</sup> activation: Identification of an activating kinase," <i>Mol. Biol. Cell</i> , 3(1):13-27 (Jan. 1992).	
VB	BM	SUTTERLÜTY, H. et al., "p45 <sup>SKP2</sup> promotes p27 <sup>Kip1</sup> degradation and induces S phase in quiescent cells," <i>Nat. Cell Biol.</i> , 1(4):207-214 (Aug. 1999).	
VB	BN	TORCHINSKY, C. et al., "Regulation of p27 <sup>Kip1</sup> during gentamicin mediated hair cell death," <i>J. Neurocytol.</i> , 28:913-924 (Oct.-Nov. 1999).	
VB	BO	TOYOSHIMA, H. and HUNTER, T., "p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21," <i>Cell</i> , 78(1):67-74 (Jul. 15, 1994).	
VB	BP	TSVETKOV, L. et al., "p27 <sup>Kip1</sup> ubiquitination and degradation is regulated by the SCF <sup>SKP2</sup> complex through phosphorylated Thr187 in p27," <i>Curr. Biol.</i> , 9(12):661-664 (Jun. 7, 1999).	
VB	BQ	VLACH, J. et al., "Growth arrest by the cyclin-dependent kinase inhibitor p27 <sup>Kip1</sup> is abrogated by c-Myc," <i>EMBO J.</i> , 15(23):6595-6604 (Dec. 2, 1996).	
VB	BR	XIONG, Y. et al., "p21 is a universal inhibitor of cyclin kinases," <i>Nature</i> , 366(6456):701-704 (Dec. 16, 1993).	

Examiner Signature	/Valarie Bertoglio/	Date Considered	05/31/2006
-----------------------	---------------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.